Neurocentria
CA - Walnut CreekBiotechnology
Focus: Neurocentria is a public biotech focused on small-molecule therapeutics for neurological disorders, headquartered in Walnut Creek, CA since 2012. The company maintains a clinical-stage pipeline targeting high-burden CNS indications like ADHD, schizophrenia, and Alzheimer's disease.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Neurocentria?
AI assessmentSuitable for specialists committed to CNS drug development who tolerate binary clinical risk and limited hiring velocity in exchange for focused expertise and public-market stability.
Why Work Here
- Pipeline breadth across ADHD, schizophrenia, anxiety, and Alzheimer's disease with two Phase 2/3 programs (NRCT-101SR) offering near-term catalysts for career progression
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
7 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
L-Threonic Acid Magnesium Salt
Attention Deficit/Hyperactivity DisorderClinical Trials (1)
NCT02558790L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD
Phase 2Help build intelligence for Neurocentria
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.